8-K: Dyadic Reports Q2 2025 Results, Strategic Shift

Dyadic International, Inc. announced its second quarter 2025 financial results, highlighting a strategic transformation towards commercial operations and key product advancements.

Summary

• Dyadic International, Inc. has rebranded as Dyadic Applied BioSolutions, reflecting a strategic shift from a technology development organization to a market-facing, revenue-focused biotechnology company.
• The company completed a strategic leadership and operational transformation to prioritize commercial execution and long-term value creation.
• A public offering of 6,052,000 shares of common stock at $0.95 per share was completed on August 1, 2025, generating approximately $5.3 million in net proceeds.
• Total revenue for the three months ended June 30, 2025, increased to $967,000, up from $386,000 for the same period a year ago.
• Net loss for Q2 2025 decreased to $1,794,000, or $0.06 per share, compared to $2,045,000, or $0.07 per share, in Q2 2024.
• Loss from operations for Q2 2025 decreased to $1,729,000 from $2,043,000 in Q2 2024.
• Key development and commercial milestones were achieved in life sciences and nutrition markets, with multiple recombinant protein programs advancing toward commercialization.
• Cash, cash equivalents, restricted cash and cash equivalents, and investment grade securities totaled approximately $7.3 million as of June 30, 2025.

Sentiment

Score: 7

Explanation: The company demonstrates strong positive momentum with significant revenue growth, reduced losses, a successful capital raise, and a clear strategic shift towards commercialization. Multiple product advancements and partnerships indicate future revenue potential. However, the company still operates at a net loss and has negative stockholders' equity, indicating ongoing financial challenges despite the progress.

Positives

• Total revenue increased by 150.5% to $967,000 in Q2 2025 compared to $386,000 in Q2 2024, driven by milestone and grant revenue.
• Net loss decreased by 12.2% to $1,794,000 in Q2 2025 from $2,045,000 in Q2 2024.
• Loss from operations decreased by 15.3% to $1,729,000 in Q2 2025 from $2,043,000 in Q2 2024.
• Successful completion of a $5.3 million equity offering on August 1, 2025, strengthening liquidity and funding growth.
• Achieved $1.0 million in milestone payments to date from Proliant Health and Biologics for recombinant serum albumin, with an additional $500,000 expected in Q3 2025.
• Received a second installment of $1.5 million in non-dilutive funding from the Gates Foundation for low-cost monoclonal antibodies.
• Expected to receive a $250,000 milestone payment from Inzymes for productivity achievements.
• Launched EN3ZYME, an enzyme cocktail, in partnership with Fermbox Bio, with an expected 50/50 revenue profit share from commercial sales.
• General and administrative expenses decreased by 10.6% to $1,437,000 in Q2 2025.

Negatives

• Cash, cash equivalents, restricted cash and cash equivalents, and investment grade securities decreased to $7.3 million as of June 30, 2025, from $9.3 million as of December 31, 2024 (prior to the August 1, 2025 equity offering).
• Research and development expenses increased to $629,000 in Q2 2025 from $516,000 in Q2 2024 due to a rise in active internal research initiatives.
• The company continues to report a net loss of $1,794,000 for Q2 2025.
• Total current assets decreased from $9,827,668 as of December 31, 2024, to $7,406,739 as of June 30, 2025.
• Total liabilities increased from $7,459,985 as of December 31, 2024, to $8,667,747 as of June 30, 2025.
• Total stockholders' equity was negative $529,701 as of June 30, 2025.

Risks

• History of net losses.
• Market and regulatory acceptance of microbial protein production platforms and other technologies.
• Failure to commercialize microbial protein production platforms or other technologies.
• Competition, including from alternative technologies.
• Results of nonclinical studies and clinical trials.
• Capital needs.
• Changes in global economic and financial conditions.
• Reliance on information technology.
• Dependence on third parties.
• Government regulations and environmental, social and governance issues.
• Intellectual property risks.
• Ability to comply with the listing standards of the Nasdaq Stock Market LLC.

Future Outlook

The company anticipates accelerating its shift from R&D-driven to commercially focused, with expected upcoming launches of DNase I and recombinant human albumin through its partnership with Proliant Health and Biologics. These are viewed as the first of a potential series of product-driven revenue catalysts. Dyadic also expects to continue advancing its pipeline, including recombinant transferrin, growth factors, and an expanded nucleic acid enzymes portfolio, with sampling and validation efforts ongoing and results expected into late 2025 and 2026. Further commercialization efforts are progressing for non-animal dairy applications and bio-industrial products, with ongoing negotiations for licensing and supply agreements and exploration of additional enzyme opportunities.

Management Comments

• "Q2 marked a pivotal turning point in Dyadic's evolution as we advanced our transformation from a technology development organization to a market-facing, revenue-focused biotechnology company. Our rebranding to Dyadic Applied BioSolutions and strategic realignment have sparked renewed interest across our ecosystem from partners and customers to investors and reflect our commitment to commercial execution."
• "The recent capital raise should enable us to accelerate our shift from R&D-driven to commercially focused, and we are particularly excited about the anticipated upcoming launches of DNase I and recombinant human albumin through our partnership with Proliant Health and Biologics, the first of a potential series of product-driven revenue catalysts as we continue delivering on our mission to engineering proteins that power progress."

Industry Context

Dyadic's strategic transformation and focus on scalable production of high-value, precision-engineered functional input proteins align with broader industry trends towards non-animal sources in life sciences, food and nutrition, and industrial biotechnology. The company's C1 and Dapibus expression systems aim to disrupt the cost, speed, and scalability of protein production, positioning it within the growing market for sustainable and efficient biomanufacturing solutions. Participation in initiatives like the European Vaccines Hub (EVH) further integrates Dyadic into global efforts to accelerate and reduce the cost of vaccine and antibody production.

Related Party Transactions

• Interest expense related party of $24,377 for the three months ended June 30, 2025 ($52,469 for the same period a year ago).
• Accrued interest related party of $21,800 as of June 30, 2025 ($27,173 as of December 31, 2024).
• Convertible notes, net of issuance costs related party of $1,070,971 as of June 30, 2025 ($1,065,876 as of December 31, 2024).

Stakeholder Impact

• Shareholders: Experienced dilution from the recent equity offering but benefit from strengthened liquidity and potential for future revenue catalysts from commercialization efforts.
• Partners/Customers: Benefit from the company's strategic realignment towards commercial execution, leading to advanced product development and anticipated launches of high-value proteins.
• Employees: The strategic transformation and increased internal research initiatives suggest a continued focus on core business activities and potential for growth.
• Creditors: Total liabilities increased, but the recent capital raise provides additional cash, potentially improving the company's ability to meet obligations.

Next Steps

• Anticipated commercial launches of DNase I and recombinant human albumin through partnership with Proliant Health and Biologics.
• Expected third milestone payment of $500,000 from Proliant in Q3 2025.
• Sampling and validation for recombinant transferrin actively underway in Q3 2025.
• Ongoing characterization and validation for recombinant Fibroblast Growth Factor (FGF), with sampling underway.
• Production validation and research-grade material manufacturing for RNase-free DNase-1 underway, with ongoing discussions for potential partnerships.
• Further optimization and results expected by late 2025 and into 2026 for expanded Nucleic Acid Enzymes Portfolio.
• Active negotiation of licensing and supply agreements for recombinant alpha-lactalbumin, with sampling expected in Q4 2025.
• Continued optimization and characterization for human lactoferrin, with sampling expected to begin in the second half of 2025.
• Scale-up and commercialization efforts for the first non-animal dairy enzyme progressing toward a late 2025 launch.
• Exploration of additional enzyme opportunities under development with Fermbox Bio.
• Hosting an earnings call on August 13, 2025, at 5:00 pm ET.

Key Dates

Recommendation

The company is undergoing a significant strategic transformation from R&D to commercial operations, showing promising revenue growth and reduced net losses in Q2 2025. The recent $5.3 million equity raise strengthens its financial position to fund this shift and accelerate product launches. While the company still operates at a net loss and has negative stockholders' equity, the progress in commercial milestones and partnerships, particularly the anticipated launches of DNase I and recombinant human albumin, indicates potential future revenue catalysts. Investors should monitor the execution of the commercial strategy and the realization of anticipated product revenues before a stronger buy recommendation.

Keywords

Biotechnology, Protein Production, C1 Platform, Dapibus, Life Sciences, Food and Nutrition, Bio-industrial, Recombinant Proteins, Cell Culture Media, Enzymes, Monoclonal Antibodies, Vaccines, DNase I, Serum Albumin, Transferrin